FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1 / 3 mRNA Expression.

To our knowledge, these are the first data to compare FGFR-directed therapy with chemotherapy in patients with -altered UC, showing comparable efficacy and manageable safety. Exploratory testing suggested DNA alterations in association with / mRNA overexpression may be better predictors of rogaratinib response.